How we know

Medical review

This site's subject is price. Where it touches clinical ground, it stays inside what public labelling and named trials support, and it says plainly when a claim has not been reviewed by a clinician.

Current status

Medical review is currently pending. No clinician has signed off on the clinical content of this site, and we will not name one who has not. Until a named, credential-verified reviewer is in place, treat every clinical statement here as what it is: a summary of public FDA labelling and published trial results, assembled by a pricing desk rather than by a clinician.

This is stated plainly because the alternative — a plausible name on a page nobody read — is the failure mode that makes medical review worthless everywhere it appears.

The review process

  1. Desk drafts against primary sources. Clinical statements are written only from FDA labelling and named trials with verifiable identifiers. Nothing is drawn from secondary summaries.
  2. Claim-by-claim check. Each clinical claim is checked against the source it cites, and any claim that cannot be traced is cut rather than softened.
  3. Named clinician sign-off. A licensed clinician reads the page and signs off with a date. Their name, credentials and the date appear on the page they reviewed — never sitewide as a blanket endorsement of pages they have not read.

What this site does not do

It does not recommend a medication, a dose, or a provider on clinical grounds. It does not tell you whether a GLP-1 is appropriate for you. It does not interpret your labs, your history or your insurance. Those are conversations with a licensed clinician, and no amount of price research substitutes for one.

On compounded products specifically

This site publishes pricing and program research, not medical advice. Compounded tirzepatide and semaglutide are not FDA-approved products, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed. Since the FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, compounding copies of the approved products is broadly restricted, and remaining 503A dispensing operates under documented patient-specific need in a contested legal environment. Talk to a licensed clinician before starting, changing or stopping any medication. Prices change; verify at the provider's checkout before you pay.